Corvus Pharmaceuticals, Inc.

Stocks

CRVS

US2210151005

Market Closed - Nasdaq 16:00:00 2026-10-23 EDT			5-day change	1st Jan Change
10.53 ^USD	-1.13%		+10.61%	+36.75%

09-30	Corvus Pharmaceuticals, Inc. Begins Enrollment In Phase 1b Clinical Trial Of Soquelitinib For Treatment Of Patients With Hidradenitis Suppurativa	CI
08-27	Corvus Pharmaceuticals Publishes Final Phase 1 Data from Soquelitinib Phase 1/1B T Cell Lymphoma Trial	CI

Transcript : Corvus Pharmaceuticals, Inc. - Shareholder/Analyst Call

Published on 05/14/2026 at 03:35 pm EDT - Modified on 05/14/2026 at 07:02 pm EDT

S&P Capital IQ

Presenter Speech
Richard Miller (Executives)

Welcome, everybody. My name is Richard Miller. I'm the CEO of Corvus Pharmaceuticals, and we're delighted to be conducting this webinar and in-person

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Corvus Pharmaceuticals, Inc.

09-30	Corvus Pharmaceuticals, Inc. Begins Enrollment In Phase 1b Clinical Trial Of Soquelitinib For Treatment Of Patients With Hidradenitis Suppurativa	CI
08-27	Corvus Pharmaceuticals Publishes Final Phase 1 Data from Soquelitinib Phase 1/1B T Cell Lymphoma Trial	CI
08-06	Corvus Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 06, 2026
08-06	Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-22	Corvus Pharmaceuticals, Inc. Announces Resignation of Ian T. Clark from Board of Directors, Effective July 22, 2026	CI
06-09	Angel Pharmatech Ltd. announced that it has received $13.5 million in funding from Corvus Pharmaceuticals, Inc. and other investors	CI
06-08	Angel Pharmaceuticals announced that it has received CNY 100 million in funding from Corvus Pharmaceuticals, Inc., Zhejiang Yisheng Yihua Investment Management Co., Ltd., Jiangsu Ruihua Venture Capital Management Co., Ltd. and other investors	CI
06-08	Corvus Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 11:20 AM
05-14	Corvus Pharmaceuticals, Inc. - Shareholder/Analyst Call
05-14	Corvus Pharmaceuticals, Inc. Presents Final Data From Soquelitinib Phase 1 Atopic Dermatitis Clinical Trial	CI
05-07	Corvus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-23	Corvus Pharmaceuticals, Inc. Appoints Andrew C. Chan to Board of Directors	CI
04-17	Goldman Sachs Initiates Corvus Pharmaceuticals at Buy With $40 Price Target	MT
03-13	Oppenheimer Adjusts Price Target on Corvus Pharmaceuticals to $33 From $32, Maintains Outperform Rating	MT
03-12	Corvus Pharmaceuticals, Inc., Q4 2025 Earnings Call, Mar 12, 2026